Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling.
de Lange EC, Ravenstijn PG, Groenendaal D, van Steeg TJ. de Lange EC, et al. Among authors: ravenstijn pg. AAPS J. 2005 Oct 7;7(3):E532-43. doi: 10.1208/aapsj070354. AAPS J. 2005. PMID: 16353931 Free PMC article. Review.
Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease.
Ravenstijn PG, Drenth HJ, O'Neill MJ, Danhof M, de Lange EC. Ravenstijn PG, et al. Fluids Barriers CNS. 2012 Feb 8;9:4. doi: 10.1186/2045-8118-9-4. Fluids Barriers CNS. 2012. PMID: 22316420 Free PMC article.
The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments.
Ravenstijn PG, Merlini M, Hameetman M, Murray TK, Ward MA, Lewis H, Ball G, Mottart C, de Ville de Goyet C, Lemarchand T, van Belle K, O'Neill MJ, Danhof M, de Lange EC. Ravenstijn PG, et al. J Pharmacol Toxicol Methods. 2008 Mar-Apr;57(2):114-30. doi: 10.1016/j.vascn.2007.10.003. Epub 2007 Nov 13. J Pharmacol Toxicol Methods. 2008. PMID: 18155613
A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4.
Templeton I, Ravenstijn P, Sensenhauser C, Snoeys J. Templeton I, et al. Biopharm Drug Dispos. 2016 Jan;37(1):15-27. doi: 10.1002/bdd.1992. Biopharm Drug Dispos. 2016. PMID: 26356245 Clinical Trial.
Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategy.
Samtani MN, Nandy P, Ravenstijn P, Remmerie B, Vermeulen A, Russu A, D'hoore P, Baum EZ, Savitz A, Gopal S, Hough D. Samtani MN, et al. Br J Clin Pharmacol. 2016 Nov;82(5):1364-1370. doi: 10.1111/bcp.13050. Epub 2016 Jul 24. Br J Clin Pharmacol. 2016. PMID: 27333588 Free PMC article. Clinical Trial.
18F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446.
Koole M, Schmidt ME, Hijzen A, Ravenstijn P, Vandermeulen C, Van Weehaeghe D, Serdons K, Celen S, Bormans G, Ceusters M, Zhang W, Van Nueten L, Kolb H, de Hoon J, Van Laere K. Koole M, et al. J Nucl Med. 2019 May;60(5):683-690. doi: 10.2967/jnumed.118.216747. Epub 2018 Sep 27. J Nucl Med. 2019. PMID: 30262518
Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies.
Smit JW, Oh C, Rengelshausen J, Terlinden R, Ravenstijn PG, Wang SS, Upmalis D, Mangold B. Smit JW, et al. Among authors: ravenstijn pg. Pharmacotherapy. 2010 Jan;30(1):25-34. doi: 10.1592/phco.30.1.25. Pharmacotherapy. 2010. PMID: 20030470 Clinical Trial.
Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?
Ravenstijn P, Samtani M, Russu A, Hough D, Gopal S. Ravenstijn P, et al. J Clin Psychopharmacol. 2016 Dec;36(6):744-745. doi: 10.1097/JCP.0000000000000610. J Clin Psychopharmacol. 2016. PMID: 27755158 Free PMC article. No abstract available.
Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.
Ravenstijn P, Remmerie B, Savitz A, Samtani MN, Nuamah I, Chang CT, De Meulder M, Hough D, Gopal S. Ravenstijn P, et al. J Clin Pharmacol. 2016 Mar;56(3):330-9. doi: 10.1002/jcph.597. Epub 2015 Oct 5. J Clin Pharmacol. 2016. PMID: 26189570 Clinical Trial.
Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
Gopal S, Vermeulen A, Nandy P, Ravenstijn P, Nuamah I, Buron Vidal JA, Berwaerts J, Savitz A, Hough D, Samtani MN. Gopal S, et al. Curr Med Res Opin. 2015 Nov;31(11):2043-54. doi: 10.1185/03007995.2015.1085849. Epub 2015 Oct 2. Curr Med Res Opin. 2015. PMID: 26306819
Feedback